BioLife Solutions, Inc.

Directions Website

BioLife Solutions, Inc. BioLife Solutions is now part of Repligen. Preserving the Promise™

The human body can heal itself. Repligen's stock ticker on NASDAQ is: RGEN.

Preserving the Promise™

It is our mission to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to preserve that promise. For more information, please visit www.biolifesolutions.com and follow BioLife on LinkedIn, Facebook and X. For more information about Repligen, visit their website at www.repligen.com, and follow Repligen on LinkedIn.

How do you ensure better consistency, performance, and recovery in your cell culture reagents?By starting with recombina...
10/08/2026

How do you ensure better consistency, performance, and recovery in your cell culture reagents?

By starting with recombinant proteins that are high purity, animal origin-free, and have guaranteed bioactivity. ✅

📺 Watch our latest on-demand webinar hosted by Cell & Gene Therapy Review in collaboration with Dave Briner of BioLife Solutions, and Dr. Liz Stewart of Qkine. Dave and Liz shared important reagent considerations to maximize scale-up, reproducibility, quality documentation, and regulatory readiness in your organoid or cell and gene therapy processes.

Learn more: https://www.cellgenetherapyreview.com/3980-Webinars/627505-From-bench-to-batch-Building-reproducible-cell-and-gene-therapy-workflows-with-GMP-ready-reagents/?partnerref=biolifesolutions

The ScaleReady and Emily Whitehead Foundation G-Rex Grant Tour is back on the road and heading to NYC on Monday, October...
10/01/2026

The ScaleReady and Emily Whitehead Foundation G-Rex Grant Tour is back on the road and heading to NYC on Monday, October 12. 🏙️🍎

♾️ We’re excited to present a case study at this event that was conducted by CTMC and published in collaboration with Cell & Gene Therapy Insights called, “Proof of concept of a fully enclosed CAR-T process without use of a biosafety cabinet.”

♾️ The study tested CellSeal® Connect vials and CellSeal® CryoCase as closed-system container alternatives to conventional vials. Both CellSeal containers were found to enable closed processing and less reliance on a BSC in CAR-T manufacturing. Cell viability and expansion were similar. Less reliance on BSCs could lower facility complexity, contamination risk, and production costs.

🗣️ Don’t forget to stop by the BioLife table to chat with Amy Ma and Dave Briner.

Register for the event: https://bit.ly/4hb8hhc

Recombinant proteins must deliver reproducible biological activity while meeting the quality requirements of increasingl...
09/30/2026

Recombinant proteins must deliver reproducible biological activity while meeting the quality requirements of increasingly advanced cell and gene therapy and organoid workflows.

🧪 To support these complex workflows, BioLife Solutions is thrilled to offer a new FREE sample program from our cytokine and growth factor portfolio for you to test and validate.

🧪 BioLife offers IL-2, IL-7, IL-15, and FGF-2. In this new program you can select up to THREE free proteins.

While you may already have a protein supplier, we are encouraging groups to validate BioLife proteins as their secondary supplier for our high performance and consistency. We’re here to answer any technical questions and help you achieve improved cell culture outcomes. 🔎

👉 Request your free samples: https://go.biolifesolutions.com/l/103972/2026-09-14/5ybjj4

The development of scalable, allogeneic cancer therapies from induced pluripotent stem cell (iPSC)-derived natural kille...
09/29/2026

The development of scalable, allogeneic cancer therapies from induced pluripotent stem cell (iPSC)-derived natural killer cells (iNKs) depends on the ability to maintain cellular quality and function throughout manufacturing, storage, distribution, and subsequent clinical use.

Since freezing and thawing can impair both cell recovery and NK-cell effector activity, optimized cryopreservation approaches are needed.

❄️ In a new study published with Cell & Gene Therapy Insights, Dr. Robert Ben, Senior Director, and Dr. Anna Jezierski of the National Research Council of Canada, examined whether incorporating a small-molecule ice recrystallization inhibitor (IRI) into BioLife’s CryoStor® CS10 freeze media could improve the preservation of iNKs during extended cryogenic storage.

💡 Following three and five months of cryogenic storage, cells preserved with IRI-supplemented CryoStor CS10 demonstrated significantly greater cytotoxic activity. This factor and other positive preliminary results indicate that targeting ice recrystallization may provide a complementary approach to conventional cryopreservation for maintaining the functional properties of iNKs during prolonged cryostorage.

Find out more ➡️: https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3971/evaluation-of-ice-recrystallization-inhibitors-for-preserving-the-postthaw-function-of-ipscderived-natural-killer-cells

09/25/2026

This is our final post of our week-long dive into ‘Biopreservation Best Practices’ shared from Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer. These snippets were taken from Dr. Mathew’s talk at the BioProcess International West Conference earlier this year.

🚨 An important question is posed in this portion of the presentation:

Do you understand the difference between perceived viability (yield) vs. true viable recovery?

⌛ Dr. Mathew discusses the concepts of Delayed Onset Cell Death (DOCD), apoptosis, necrosis, and other long-term issues that could show up later, 24 – 72 hours after thawing cells, not immediately or a few hours post-thaw.

✅ Running multiple assays, tiers, and time frames will help you to fully understand, characterize, and validate your cell product.

Check out the data in the video. 🔎

09/24/2026

In today’s post Dr. Aby J. Mathew explores a cell’s experience during biopreservation processes (freezing and thawing), that causes stress and other negative effects – such as slow or dysfunctional membrane pumps and ice crystal growth. ❄️

While presenting at the BioProcess International West Conference in San Diego earlier this year, Dr. Mathew, our Executive Vice President and Chief Scientific Officer, suggested that utilizing an optimized biopreservation media can help mitigate these various stressors and improve cell function. 📈 🎯

🎥 Learn more about ‘Cell Stressors’ in this video clip.

09/23/2026

It’s day three of our week-long series exploring key biopreservation best practices that Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, shared during his presentation at the spring BioProcess International West Conference.

💥 In this portion, Dr. Mathew discusses common cellular responses to biopreservation processes that can cause challenges and stress to cells at multiple levels AND at multiple points in your workflow; all of which may impact your cells negatively.

💭 If you’re not seeing desired cell performance and outcomes, then this video clip is a must-see for the cell environment you should consider, such as decreased metabolic activity and the formation of extra- and intra-cellular ice.

Watch now. 👇

09/22/2026

As we mentioned on Monday, Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, gave a presentation called “Biopreservation Best Practices for Cell-based Products” at BioProcess International West earlier this year.

Today we’re focusing on how cryopreservation is not just ‘one step’ in cell and gene therapy production.

⚠️ Challenge: Within a cryopreservation process, there are multiple steps and considerations that can greatly affect your outcome including: your choice of media solutions, cell concentrations, temperature, cooling & thawing rates, wash post-thaw or not, and more.

🧩 Solution: Analyze how you can optimize each step within this process. Look at your upstream and downstream processes too, BEFORE you get to the clinical phase and commercialization.

Hear what Dr. Mathew has to say in less than two minutes below. 🎤

Do you have specific cryopreservation questions? Ask us here: https://www.biolifesolutions.com/cell-processing/biopreservation-media/ask-the-scientists

09/21/2026

During the Bioprocessing International West Conference earlier this year in San Diego, Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, gave a presentation called “Biopreservation Best Practices for Cell-based Products”.

This week in five posts, we are highlighting a few key topics from Dr. Mathew’s talk that stress the importance of implementing these best practices.

⚠️ Challenge: Traditional methods in the lab don’t always translate to cell therapy manufacturing or the desired cell efficacy.

🧩 Solution: When assessing your processes, reach out to a partner that can help you optimize and translate your workflows to a GMP-ready manufacturing environment.

🎬 Watch this quick clip to hear Dr. Mathew’s take.

Address

3303 Monte Villa Pkwy, Suite 310
Bothell, WA
98021

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when BioLife Solutions, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share